Archived explainer. For the current picture see today's AMRN page.
AMARIN CORP PLC ADR (AMRN) is drawing unusual attention today. Our newswire has captured 1 story on AMRN across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Amarin Corp PLC ADR (AMRN) is moving in early trading as new data from a post hoc analysis of the REDUCE-IT trial highlights potential long-term cardiovascular benefits of its drug Vascepa. The findings suggest that patients taking icosapent ethyl for at least 18 months experienced a roughly 30% lower risk of major cardiovascular events. This development is drawing investor attention to the company’s ongoing clinical and commercial progress.
A new post hoc analysis of the REDUCE-IT trial, published recently, found that patients using Vascepa for 18 months or more saw a significant reduction in the risk of major adverse cardiovascular events. The relative risk reduction of about 30% was noted, with a hazard ratio of 0.73 observed even after discontinuation of the drug. Amarin is highlighting these findings as evidence of Vascepa’s long-term therapeutic value, potentially reinforcing its role in cardiovascular care.
In related news, JP Morgan recently reinstated an Underweight rating for Amarin, setting a $13 price target. Meanwhile, the company reported Q2 sales of $42.211 million, which fell short of the $44.550 million estimate. Amarin also noted recent FDA approvals of injectable apolipoprotein C-III therapies for severe hypertriglyceridemia, expanding the treatment landscape for cardiovascular conditions.
AMRN has a market capitalization of $295.1 million and remains unprofitable, with a trailing twelve-month (TTM) earnings per share (EPS) of -1.30. Its revenue has declined by 15.1% over the same period, and its net margin stands at -14.6%. The stock has traded between $12.96 and $20.90 over the past 52 weeks, with a beta of 0.76, indicating lower volatility than the broader market.
Investors should monitor Amarin’s upcoming earnings report and continued coverage from analysts. The company’s ability to translate clinical data into commercial success will remain a key focus for the market.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
New REDUCE-IT post hoc analysis: Amarin’s Vascepa/icosapent ethyl shows ~30% lower major CV event risk with 18+ months use; get investor takeaways.
More on AMRN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AMRN move explainers: 2026-08-31